MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

Abstract

The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of alpha-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with alpha-particle emitters. Although alpha-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted alpha-particle emitter therapy and to provide guidance and recommendations for human alpha-particle emitter dosimetry.

DOI: 10.2967/jnumed.108.058651

13 Figures and Tables

01002002011201220132014201520162017
Citations per Year

488 Citations

Semantic Scholar estimates that this publication has 488 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Sgouros2010MIRDPN, title={MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.}, author={George Sgouros and John C. Roeske and Michael R McDevitt and Stig Palm and Barry J. Allen and Darrell R. Fisher and Aaron B. Brill and Hong Chuan Song and Roger W. Howell and Gamal Akabani and Wesley E. Bolch and Ruby F . Meredith and Barry W. Wessels and Pat Zanzonico}, journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine}, year={2010}, volume={51 2}, pages={311-28} }